Stoke Therapeutics, Inc.
STOK
$11.53
-$0.29-2.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,661.12% | 707.07% | 47.94% | 294.72% | -18.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,661.12% | 707.07% | 47.94% | 294.72% | -18.17% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3,661.12% | 707.07% | 47.94% | 294.72% | -18.17% |
| SG&A Expenses | 43.38% | 21.06% | 23.57% | 27.44% | 0.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.23% | 11.98% | 14.26% | 11.02% | 9.20% |
| Operating Income | 492.08% | 53.85% | -10.17% | 11.79% | -14.91% |
| Income Before Tax | 532.84% | 61.12% | -7.69% | 16.18% | -16.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 527.99% | 61.12% | -7.69% | 16.18% | -16.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 527.99% | 61.12% | -7.69% | 16.18% | -16.98% |
| EBIT | 492.08% | 53.85% | -10.17% | 11.79% | -14.91% |
| EBITDA | 501.73% | 54.68% | -10.78% | 11.81% | -15.42% |
| EPS Basic | 442.07% | 69.35% | 15.39% | 33.57% | -7.60% |
| Normalized Basic EPS | 445.99% | 69.34% | 15.38% | 33.58% | -7.58% |
| EPS Diluted | 433.16% | 69.35% | 15.39% | 33.57% | -7.60% |
| Normalized Diluted EPS | 437.04% | 69.34% | 15.38% | 33.58% | -7.58% |
| Average Basic Shares Outstanding | 25.12% | 26.85% | 27.28% | 26.20% | 8.72% |
| Average Diluted Shares Outstanding | 28.44% | 26.85% | 27.28% | 26.20% | 8.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |